- Details
- Kristen Scarpato, Svetlana Avulova, and Anne Schuckman join Sima Porten in this conversation on the realities of diagnosis and treatment of bladder cancer in women. They start by evaluating a patient case to highlight some women who present with bladder cancer and discuss what's most important when we talk about caring for these patients and how to improve care. Biographies: Sima P. Porten, MD, MP...
|
- Details
- Alicia Morgans is joined by Jeannie Hoffman-Censits and Elizabeth Guancial to discuss the challenges women face navigating a bladder cancer diagnosis. In 2022, the American Cancer Society estimates more than 81,000 will be diagnosed with bladder cancer in the United States. Of those, 61,700 will be men, and 19,480 will be women. Drs. Morgans, Hoffman-Censits, and Guancial discuss the importance of...
|
- Details
- For this Journal Club, Christopher Wallis, MD, and Zach Klasseen, MD discuss a recently published meta-analysis on treatment options for patients with non-muscle invasive bladder cancer unresponsive or refractory to BCG therapy. They provide context for this review and discuss the clinical relevance of managing the risk of recurrence in NMIBC. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncol...
|
- Details
- Siamak (Sia) Daneshmand joins Ashish Kamat in a discussion on the role of blue-light cystoscopy (BLC) in detecting invasive bladder tumors. Providing background on the beneficial use of BLC in carcinoma in situ (CIS), Dr. Daneshmand highlights the evidence on the potential of finding additional TA tumors with the use of BLC. He showcases data from a BJUI multi-institutional registry publication on...
|
- Details
- Ashish Kamat is joined by Patrick Lewicki to discuss the recent publication on the underutilization of Blue Light Cystoscopy (BLC) in the United States. Studying the use of BLC in the Premier Healthcare Database, the findings demonstrate a low level of BLC use despite guideline recommendations and evidence demonstrating the benefit for its use in the management of non-muscle invasive bladder cance...
|
- Details
- In this UroToday journal club, Christopher Wallis and Zachary Klaassen highlight a European Urology Focus publication entitled Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States. Blue light cystoscopy (BLC) for the management of nonmuscle invasive bladder cancer (NMIBC) is an evidence- and guideline-supported intervention that has been shown to increase cancer detect...
|
- Details
- In this 2021 LUGPA CME presentation, Michael O’Donnell discusses intravesical therapies for non-muscle invasive disease. He covers the background of indications for intravesical therapy, managing recurrent non-muscle invasive bladder cancer (NMIBC) including BCG failures and BCG unresponsiveness. Biographies: Michael A. O’Donnell, MD, Richard D. Williams Professor & Director of Urologic Oncology,...
|
- Details
- Joining Ashish Kamat is Arjun Balar, both experts in the field of bladder cancer and each closely involved with the FDA approval of pembrolizumab in the BCG-unresponsive bladder cancer population. Dr. Balar outlines the history of the drug, how the study which led to the FDA approval in NMIBC was designed. Dr. Balar also expands in his approach to counseling his patients who are considering pembro...
|
- Details
- Richard Matulewicz joins Ashish Kamat presenting findings on the association of smoking status on recurrence of non-muscle invasive bladder cancer (NMIBC) in a contemporary cohort of patients with predominantly high-risk, recurrent NMIBC managed with photodynamic enhanced cystoscopy. A retrospective study was conducted in a multi-institutional registry. Smoking has a strong causal association with...
|
- Details
- Stephen Williams joins Ashish Kamat presenting findings on macro and microeconomics of blue light cystoscopy (BLC) with CYSVIEW® in the care of patients with non-muscle invasive bladder cancer, a Urologic Oncology Seminars and Original Investigations publication. The aim of the study was to determine the estimated budget impact to practices that incorporate blue light cystoscopy with hexaminolevul...
|
